We aim to provide a clinically focused review of the neurobiological literature in body dysmorphic disorder (BDD), with a focus on structural and functional neuroimaging.
Conclusions:
There has been a recent influx of studies examining the underlying neurobiology of BDD using structural and functional neuroimaging methods. Despite obvious symptom similarities with obsessive–compulsive disorder (OCD), no study to date has directly compared the two groups using neuroimaging techniques. Studies have established that there are limbic and visual cortex abnormalities in BDD, in contrast to fronto-striatal differences in OCD. Such data suggests affect or visual training maybe useful in BDD.
American Psychiatric Publishing, Diagnostic and statistical manual of mental disorders. 5th edition. Washington, DC: American Psychiatric Publishing, 2013.
2.
BuhlmannUGlaesmerHMewesR. Updates on the prevalence of body dysmorphic disorder: A population-based survey. Psychiatry Res2010; 178: 171–175.
3.
PhillipsKADidieERMenardW. Clinical features of body dysmorphic disorder in adolescents and adults. Psychiatry Res2006; 141: 305–314.
4.
PaulsDLAbramovitchARauchSL. Obsessive-compulsive disorder: An integrative genetic and neurobiological perspective. Nat Neurosci Rev2014; 15: 410–424.
5.
BuchananBRossellSLMallerJ. Regional brain volumes in body dysmorphic disorder compared to controls. Aust N Z J Psychiatry2014; 48: 654–662.
6.
RauchSLPhillipsKASegalE. A preliminary morphometric magnetic resonance imaging study of regional brain volumes in body dysmorphic disorder. Psychiatry Res2003; 122: 13–19.
7.
AtmacaMBingolIAydinA. Brain morphology of patients with body dysmorphic disorder. J Affect Disord2010; 123: 258–263.
8.
FeusnerJDTownsendJBystritskyA. Regional brain volumes and symptom severity in body dysmorphic disorder. Psychiatry Res2009; 172: 161–167.
9.
BuchananBRossellSLMallerJ. Brain connectivity in body dysmorphic disorder compared with controls: A diffusion tensor imaging study. Psychol Med2013; 43: 2513–2521.
10.
FeusnerJDArienzoDLiW. White matter microstructure in body dysmorphic disorder and its clinical correlates. Psychiatry Res2013; 211: 132–140.
11.
ArienzoDLeowABrownJA. Abnormal brain network organization in body dysmorphic disorder. Neuropsychopharmacology2013; 38: 1130–1139.
12.
de WitSJAlonsoPSchwerenL. Multicenter voxel-based morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder. Am J Psychiatry2014; 171: 340–349.
13.
van den HeuvelOARemijnsePMataix-ColsD. The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. Brain2009; 132: 853–868.
14.
KochKReessTRusOG. Diffusion tensor imaging (DTI) studies in patients with obsessive-compulsive disorder (OCD): A review. J Psychiatr Res2014; 54: 26–35.
15.
FeusnerJDTownsendJBystritskyA. Visual information processing of faces in body dysmorphic disorder. Arch Gen Psychiatry2007; 64: 1417–1425.
16.
FeusnerJDMoodyTHembacherE. Abnormalities of visual processing and frontostriatal systems in body dysmorphic disorder. Arch Gen Psychiatry2010; 67: 197–205.
17.
FeusnerJDHembacherEMollerH. Abnormalities of object visual processing in body dysmorphic disorder. Psychol Med2011; 41: 2385–2397.
18.
BohonCHembacherEMollerH. Nonlinear relationships between anxiety and visual processing of own and others’ faces in body dysmorphic disorder. Psychiatry Res2012; 204: 132–139.
19.
TohWLRossellSLCastleDJ. Body dysmorphic disorder: A review of current nosological issues and associated cognitive deficits. Curr Psychiatry Rev2009; 5: 261–270.
20.
BuchananBRossellSLCastleDJ. Body dysmorphic disorder: A review of nosology, cognition and neurobiology. Neuropsychiatry2011; 1: 71–80.
21.
PhillipsKAHollanderE. Treating body dysmorphic disorder with medication: Evidence, misconceptions and a suggested approach. Body Image2008; 5: 13–27.
22.
PhillipsKANajjarF. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry2003; 64: 715–720.
23.
PhillipsKA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol2006; 21: 177–179.
24.
PhillipsKAMcElroySLDwightMM. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry2001; 62: 87–91.
25.
AllenAHadleySJKaplanA., An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr2008; 13: 138–144.
26.
PhillipsKAAlbertiniR.S.RasmussenS.A. A randomised placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry2002; 59: 381–388.
27.
HollanderEAllenAKwonJ., Clomipramine versus desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry1999; 56: 1033–1039.
28.
MancusoSGKnoesenNCastleDJ. Delusional versus nondelusional body dysmorphic disorder. Compr Psychiatry2010; 51: 177–182.
29.
PhillipsKA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry2005; 162: 1022–1023.
30.
PhillipsKA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry2005; 162: 377–379.
31.
VealeDAnsonMMilesS. Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: A randomised controlled trial. Psychother Psychsom2014; 83: 341–353.
32.
WilhelmSPhillipsKDidieE. Modular cognitive-behavioral therapy for body dysmorphic disorder: A randomized controlled trial. Behav Ther2014; 45: 314–327.
MacoveanuJFisherPHaahrME. Effects of selective serotonin reuptake inhibition on neural activity related to risky decisions and monetary rewards in healthy males. Neuroimage2014; 99: 434–442.
35.
ShinDJJungWHeY. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol Psychiatry2014; 75: 606–614.
36.
FrommannNStreitMWölwerW. Remediation of facial affect recognition impairments in patients with schizophrenia: A new training program. Psychiatry Res2003; 117: 281–284.
37.
WölwerWFrommannNHalfmannS., Remediation of impairments in facial affect recognition in schizophrenia: Efficacy and specificity of a new training program. Schizophr Res2005; 80: 295–303.
